What You Need to Know
• The Trump administration proposed a new rule to prevent hospitals from marking up discounted drugs for Medicare patients.
• The rule targets hospitals participating in the 340B program, which allows them to buy drugs at reduced prices.
• The Centers for Medicare & Medicaid Services estimates the rule could save Medicare patients $1.1 billion next year.
The Trump administration, led by former President Donald Trump, announced a proposal on Thursday aimed at preventing hospitals from charging excessive markups on discounted drugs for Medicare patients. This rule specifically targets hospitals that participate in the 340B program, which enables them to purchase outpatient prescription drugs at lower prices. Currently, many hospitals can bill insurers at rates higher than their acquisition costs, resulting in increased expenses for patients. The Centers for Medicare & Medicaid Services estimates that the average Medicare Part B beneficiary receiving these drugs could save approximately $800 annually in co-payments, leading to an overall savings of $1.1 billion for all beneficiaries. Over the next decade, these savings could accumulate to about $20 billion, although the proposal was not shared with hospital groups prior to its announcement.
Why It Matters
This proposal is significant as it addresses the rising healthcare costs impacting U.S. families, particularly during an election year. The 340B program was designed to help healthcare providers extend limited federal resources to serve more patients effectively. However, it has been a contentious issue between hospitals and pharmaceutical companies, with both sides lobbying for changes to the program. The potential financial impact on hospitals could affect the services they provide and employment in their communities, making this rule a critical point of discussion in healthcare policy.
Read the Full Story →
